truncating CHD7 mutations in 5/20 patients with phenotypically 22q11.2 deletion syndrome. Differentiating between CHARGE and 22q11.2 deletion syndromes can be challenging. CHD7 and TBX1 probably share a molecular pathway or have common target genes in affected organs. We strongly recommend performing CHD7 analysis in patients with a 22q11.2 deletion phenotype without TBX1 haploinsufficiency and conversely, performing a genome-wide array in CHARGE syndrome patients without a CHD7 mutation.
, and SOX2 anophthalmia syndrome [Engelen et al., 2011] . The most striking similarity of clinical features, however, is seen with 22q11.2 deletion syndrome as illustrated by Jyonouchi et al.[2009] . Here, we further explored the clinical similarities between CHARGE syndrome and 22q11.2 deletion syndrome.
CHARGE syndrome has an estimated birth incidence of 5.8-6.7 per 100,000 live births [Janssen et al., 2012] . A patient is currently diagnosed with CHARGE syndrome if the clinical diagnostic criteria of Blake et al. [1998] or of Verloes [2005] are fulfilled. The major clinical features include choanal atresia, coloboma of the eye, hypoplastic semicircular canals, external ear anomalies, and cranial nerve dysfunction (as summarised in fig. 1 ) [Bergman et al., 2011b] . CHARGE syndrome is inherited in an autosomal dominant fashion, but most cases are sporadic due to de novo mutations in the CHD7 gene [Zentner et al., 2010b; Bergman et al., 2011b] . CHD7 codes for a chromodomain helicase DNA-binding protein that has a cell type-specific and embryonic stage-dependent function in regulating the expression of other developmental genes [Vissers et al., 2004; Schnetz et al., 2009; Zentner et al., 2010a] . Heterozygous CHD7 mutations are found in more than 90% of the patients, who fulfil the clinical criteria of CHARGE syndrome, but can also be detected in patients with an atypical phenotype [Jongmans et al., 2006; Bergman et al., 2011b] .
Chromosome 22q11.2 microdeletions have an estimated birth incidence between 10 and 26 per 100,000 live births and cause a highly variable clinical phenotype including velocardiofacial syndrome (OMIM 192430) which is the combination of velopharyngeal incompetence and other palate abnormalities, congenital heart defects, and dysmorphic facial features. DiGeorge syndrome (OMIM 188400) is another associated phenotype that includes features of congenital heart defects of the outflow tract, hypocalcaemia and immunodeficiency [McDonald-McGinn et al., 1993; Schwinger et al., 2010; McDonald-McGinn and Sullivan, 2011] . Since velocardiofacial syndrome and DiGeorge syndrome describe variable clinical expressions of the same entity, the term 22q11.2 deletion syndrome is now more commonly used (features summarised in fig. 1 ) [Jyonouchi et al., 2009; McDonald-McGinn and Sullivan, 2011] . This syndrome is inherited in an autosomal dominant manner from a [Schwinger et al., 2010; Gennery, 2012] . Mutations in the TBX1 gene located in the commonly deleted region cause a similar phenotype, and thus TBX1 haploinsufficiency appears to significantly contribute to the features of 22q11.2 deletion syndrome [Merscher et al., 2001] . The overlap between CHARGE syndrome and 22q11.2 deletion syndrome has long been recognised [Emanuel et al., 1992; de Lonlay-Debeney et al., 1997; Digilio et al., 1997; Devriendt et al., 1998; Herman and Siegel, 1998 ]. The overlapping clinical features include congenital conotruncal heart defects, cleft palate, ear abnormalities, hearing loss, growth deficiency, developmental delay, renal abnormalities, hypocalcaemia, and immune deficiency [Jyonouchi et al., 2009; Bergman et al., 2011b] . Clinical features like coloboma, choanal atresia, facial nerve palsy, tracheo-oesophageal fistula, hypoplastic semicircular canals, micropenis, or hypogonadotropic hypogonadism generally occur more often in patients with CHARGE syndrome than in those with 22q11.2 deletion syndrome, although not exclusively (see fig. 1 ). Because of the clinical resemblance between the 2 syndromes, in our recent review, we recommended that CHD7 is a good candidate gene to analyse in patients with clinical features of 22q11.2 deletion syndrome, but who do not have a deletion or mutation of TBX1. We further recommended that a whole-genome array should be performed in patients suspected of CHARGE syndrome but without a CHD7 mutation or deletion [Bergman et al., 2011b] .
The overlap between CHARGE and 22q11.2 deletion syndrome and the variable expression of both syndromes can hamper clinical diagnosis but also provides interesting clues to the aetiology and pathogenesis of both syndromes. We provided further details of the overlap between the 2 syndromes by describing case reports of patients diagnosed with CHARGE syndrome but carrying a 22q11.2 deletion, by reporting the typical 22q11.2 deletion features present in a CHD7-positive cohort and by describing the results of CHD7 sequencing in a cohort of patients with features of 22q11.2 deletion syndrome but without a deletion or mutation of TBX1 . The molecular pathways underlying this clinical resemblance and the implications for genetic diagnostic work were discussed.
Methods
A schematic overview of our study design is shown in figure 2 .
Patients
We described the clinical findings of 2 Dutch patients, who were diagnosed with CHARGE syndrome according to the clinical criteria of Blake et al. [1998] and/or Verloes [2005] , but who appeared to have a 22q11.2 deletion. We further summarised the available clinical data of 3 patients described in the literature with clinically typical CHARGE syndrome and a 22q11.2 deletion.
We screened our database of 802 patients with a pathogenic CHD7 mutation for clinical features more specific for 22q11.2 deletion syndrome, like hypocalcaemia, thymus anomalies and immunological problems, or who were reported to have a DiGeorge or 22q11.2 deletion phenotype.
In addition, we analysed CHD7 in a cohort of 20 patients from the Department of Paediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa., USA. These patients were selected from a cohort of 100 cases, who were clinically suspected of 22q11.2 deletion syndrome, but in whom FISH did not detect a deletion of chromosome 22q11.2 and MLPA did not find any atypical deletions of the 22q11.22 region. In the patients selected for CHD7 analysis, point mutations in the TBX1 gene had also been excluded. The 20 patients were selected, because their 238 clinical features overlapped with features seen in CHARGE syndrome, including the presence of congenital heart defects, coloboma, immune defects, ear anomalies, renal malformations, and hearing loss.
CHD7 Analysis
Blood samples from all patients were drawn after informed consent. DNA was isolated according to standard procedures. The 37 coding exons of CHD7 (exons 2-38, RefSeq NM_017780.02) and their flanking intronic sequences were amplified by PCR and sequenced as described earlier [Jongmans et al., 2006] . If no mutations were identified, CHD7 was screened for whole-exon deletions and duplications by MLPA using a commercially available set of probes: the SALSA P201 kit (MRC-Holland, Amsterdam, The Netherlands; http://www.mrc-holland.com) [Bergman et al., 2008] .
Analysis of 22q11.2 Deletions and TBX1 Sequencing
Patients gave informed consent, and blood samples were taken. 22q11.2 deletions were detected or excluded in the Dutch patients by array comparative genomic hybridisation (CGH) using an Agilent 180 K oligonucleotide array (custom design no. 023363, Agilent Technologies Incorporation, Santa Clara, Calif., USA) and/or FISH using probe RP11-481H20 and RP11-590C5. The array CGH procedures were carried out according to the manufacturer's protocols. Normal male or female reference DNA was used as a control, and DNA analytics version 4.0.81 (Agilent Technologies Incorporation) was used to analyse the results.
The 20 Philadelphia cases were studied by FISH using the commercially available probe N25 and then analysed by an MLPA assay specific for the chromosome 22q11.22 region (MRC Holland; SALSA P250 kit) to identify deletions, whose proximal endpoints are distal to the standard FISH probes and would not have been identified in the original cohort [Jalali et al., 2008] . Point mutations in the TBX1 gene were excluded by capillary sequencing following PCR amplification as previously reported [Gong et al., 2001] . Table 1 lists all the patients with a CHARGE syndrome phenotype known to carry a 22q11.2 deletion including the 2 described below.
Results

Clinical CHARGE Patients with 22q11.2 Deletions
Patient 1. This girl was briefly described by Bergman et al. [2011b] . She was born by caesarean section because of foetal distress at 33 + 3 weeks of gestation. The pregnancy was complicated by gestational diabetes mellitus and polyhydramnios. Her birth weight was 2,830 g (97.7th percentile), and her Apgar scores were 9 and 9 after 1 and 5 min, respectively. During the first 4 weeks of life, she had feeding problems necessitating nasogastric tube feed- Features more commonly seen in CHARGE syndrome than in 22q11.2 deletion syndrome are highlighted in grey. abn. = Abnormalities; GERD = gastro-oesophageal reflux disease; SCC = semicircular canal; TE = tracheo-oesophageal anomaly; u = unexamined/unknown; + = present; -= not present. * Atresia or stenosis of choanae. ** Only if necessitating tube feeding.
ing. She was diagnosed with bronchotracheomalacia and gastro-oesophageal reflux disease. Several congenital anomalies were noticed: coloboma of the left iris and both retinas, unilateral choanal stenosis, mild pulmonic stenosis, and bilateral mixed hearing loss. A CT scan of the mastoid showed abnormal semicircular canals as well as an abnormal vestibulum and an abnormal basal convolution of the cochlea. The girl had a developmental motor delay; she started walking at the age of 2 years and 3 months. At her last examination, at the age of 3 years, she had a normal language comprehension (quotient score of 91, comprehension scales of the Dutch Reynell Developmental Language Scales). Physical examination showed simple ears, an anteriorly placed anus and a hockey-stick line crease on both palms. The diagnosis CHARGE syndrome was made based on the clinical diagnostic criteria of both Blake et al. [1998] and Verloes [2005] . Analysis of CHD7 did not show a mutation or deletion. Subsequently, array CGH showed a de novo 2.6-Mb loss of 22q11.2 (proximal breakpoint 17,210,818-17,270,293; distal breakpoint 19,891,492-19,870,318) . The deletion was confirmed by FISH analysis. Patient 2. This female infant was born prematurely at 33 + 4 weeks with a birth weight of 1,565 g (10th-20th percentile). The pregnancy was complicated by polyhydramnios. Postnatally, she experienced respiratory distress and was suspected of having a partial choanal atresia. She had a congenital heart defect consisting of arterial septal defect, ventricular septal defect and patent ductus arteriosis. Morphologic evaluation at the age of 2 days revealed microcephaly (28 cm; -5.6 SD below mean), short palpebral fissures, dysmorphic ears with broad superior crus of the antihelices, overfolded helices, and a bulbous nasal tip. CHARGE syndrome or a chromosomal abnormality was suspected, and array CGH, fundoscopy, renal ultrasound, and brain imaging with special attention for the semicircular canals were suggested. Array CGH showed a 2.9-3.0 Mb deletion of 22q11.21 (proximal breakpoint 17,210,818-17,270,293; distal breakpoint 20,142,009-20,247,225) that was confirmed by FISH analysis. The other investigations had normal results, except for subtle abnormalities of the brain MRI scan with slightly delayed myelinisation and mildly enlarged ventricles.
At the age of 2 months, the ventricular septal defect was surgically corrected. From age 4-22 months, she required a tracheostomy because of the combination of very narrow choanae and pharyngomalacia. At the age of 10 months, a gastrostoma with feeding tube were placed. At her last examination at the age of 2 years and 4 months, her height was 86 cm (-1 SD). Her head circumference was not measured, but she was normocephalic before (at the age of 22 months, her head circumference was 47.7 cm (-0.7 SD)). She was still being fed through her feeding tube and had just started to use some spoken words in addition to sign language after the removal of her tracheotomy. Table 2 summarises the 30 patients out of our international database of 802 patients, in which typical features of 22q11.2 deletion syndrome were described [Janssen et al., 2012] . We also included 3 additional patients from the literature, in whom the precise CHD7 mutation was not mentioned [Chopra et al., 2009 ]. All 33 patients had features that are more commonly seen in deletion 22q11.2 syndrome than in CHARGE syndrome. A 22q11.2 deletion was excluded in 25 of the 33 patients (76%). In one patient, a paternally inherited 2.5-Mb 22q11.23 deletion located distal to the 22q11.2 deletion syndrome region was identified in addition to the CHD7 mutation [Kaliakatsos et al., 2010] . At least, 16 of the 33 patients died in infancy.
CHD7 Mutations in
CHD7 Analysis in Patients Clinically Presenting as 22q11.2 Deletion Syndrome.
We identified 5 pathogenic CHD7 mutations in our group of 20 patients that were clinically suspected of 22q11.2 deletion syndrome. Table 3 summarises the mutations and known clinical features of the 5 patients clinically presenting as deletion 22q11.2 syndrome, but in whom a CHD7 mutation was identified. Remarkably, all 5 patients carried a truncating mutation in the CHD7 gene. In addition, we identified 2 silent CHD7 mutations (c.4014C>T, p.Gly1338Gly and c.6216C>G, p.Pro2072Pro) in 2 other patients. Both silent mutations had been identified in the 1,000 Genomes project (DbSNP rs199828744, rs188679907).
Discussion
We highlighted the clinical overlap between 22q11.2 deletion and CHARGE syndrome. Although some of the clinical features are present far more often in one of the syndromes ( fig. 1 ) , none are seen exclusively in either 22q11.2 deletion or CHARGE syndrome. For example, the presence of choanal atresia or semicircular canal hypoplasia does not exclude a 22q11.2 deletion, and severe T-cell dysfunction also occurs in CHARGE syndrome. 
Features more commonly seen in 22q11.2 deletion syndrome than in CHARGE syndrome are highlighted in grey. u = Unexamined/unknown; + = present; -= not present; abn. = abnormalities; del = deletion exon 4; fs = frameshift; developm. = developmental; GERD = gastro-oesophageal reflux disease; ID = patient ID in online database of CHD7 mutations (www.chd7.org); non = nonsense; NEC = necrotising enterocolitis; OSAS = obstructive sleep apnea syndrome; PTH def = low parathyroid hormone or hypoparathyroidism; SCC = semicircular canal; spl = splice site; TE = tracheo-oesophageal; U = mutations unknown (all patients described in Chopra et al. [2008] ); wg = whole gene; 0 = not mentioned in the online database. Remarkably, almost exclusively, we found truncating CHD7 mutations in both groups of patients suspected of having TBX1 haploinsufficiency ( tables 2 , 3 ). This is in line with our previous observation that CHD7 missense mutations result in a milder phenotype. Features also seen in 22q11.2 syndrome, like congenital heart defects and cleft palate, occur more often in patients with a truncating mutation than in those with a missense mutation [Bergman et al., 2012b] . Thus, the clinical overlap between these syndromes is predominantly seen in the more severely affected patients with a 22q11.2 deletion or CHD7 mutation.
How can we explain the remarkable clinical overlap between these 2 syndromes? It is possible that both syndromes could be present simultaneously, but this must be extremely rare, as no cases have been reported yet. However, it cannot be excluded, since not all mutations in CHD7 and TBX1 are detectable by current techniques. It is well known that no CHD7 mutation can be detected in 5-10% of the patients with a clinical diagnosis of CHARGE, suggesting either undetectable CHD7 mutations (e.g. in the promoter region) or the existence of a second gene that can cause CHARGE syndrome when mutated. Nonetheless, both syndromes should be included in a common differential diagnosis as discussed in our recent reviews [McDonald-McGinn et al., 1993; Bergman et al., 2011b; McDonald-McGinn and Sullivan, 2011] .
The most likely explanation for the phenotypic overlap between both syndromes is that the causative genes, CHD7 and TBX1 , function in the same embryonic pathway or in pathways with a common target. The CHD7 gene is expressed ubiquitously during human embryonic development with a high expression in the foetal inner ear, eye, central nervous system, and in the neural crest of the pharyngeal arches [Sanlaville et al., 2006] . The CHD7 protein belongs to the chromodomain helicase DNAbinding (CHD) family [Woodage et al., 1997] and is thought to regulate gene transcription by ATP-dependent chromatin modification during embryogenesis [Schnetz et al., 2009] . CHD7 cooperates with, amongst others, PBAF (polybromo-and BRG1-associated factor containing complex) in controlling neural crest gene expression and cell migration [Bajpai et al., 2010] .
The TBX1 gene codes for the T-box transcription factor TBX1 that regulates the expression of downstream growth and transcription factors that are involved in the development of the heart, thymus, parathyroid, and palate. TBX1 physically interferes with SMAD1, influencing its binding to SMAD4 and thus signal transduction [Fulcoli et al., 2009] . Interestingly, CHD7 was found to colocalise with SMAD1 (OMIM 601595) and other transcription factors at enhancer elements near genes that are repressed [Schnetz et al., 2010] . Thus, both TBX1 and CHD7 regulate gene transcription and might well regulate the transcription of the same genes.
Mice with heterozygous Chd7 mutations show semicircular canal defects, septal heart defects, cleft palate, choanal atresia, hyposmia, olfactory bulb anomalies, testes hypoplasia, hearing loss, and low body weight [Bosman et al., 2005; Adams et al., 2007; Hurd et al., 2007, Layman et al., 2009; Bergman et al., 2010 ] . Other CHARGE features, e.g. coloboma, external ear anomalies and tracheo-oesophageal defects, have not been reported in Chd7 -deficient mice. This discrepancy in phenotype between man and mice might be caused by species-specific differences in CHD7 requirements or differences in genetic background [Zentner et al., 2010b] . Mice with haploinsufficiency for Tbx1 show the full range of malformations that can be present in the 22q11.2 deletion syndrome [Merscher et al., 2001] . Tissue-specific conditional mutagenesis of Tbx1 has shown its role in the secondary heart field [Xu et al., 2004] , pharyngeal mesoderm [Zhang et al., 2006] , pharyngeal endoderm [Arnold et al., 2006] , pharyngeal epithelia [Zhang et al., 2005] , and otic epithelium [Xu et al., 2007] . Surprisingly, mice with a double heterozygous mutation of Chd7 and Tbx1 show a severe cardiovascular phenotype and severely reduced postnatal viability compared to mice with a heterozygous mutation of Chd7 or Tbx1 [Randall et al., 2009] . The synergistic haploinsufficiency of both genes resulted in an enhanced effect on the fourth pharyngeal arch morphogenesis, abnormal thymus development and malformations of the semicircular canals. These observations in mice together with our observations in the patients presented in this paper suggest that both genes act in the same developmental pathway. Randall et al. [2009] hypothesised that Chd7 might modulate Tbx1 expression but were unable to prove that the expression of either gene changed in mouse embryos mutated at the other locus. Hurd et al. [2011] showed that Tbx1 expression was expanded more ventrally in the develop-G e n e D is e a se C h o a n a l a tr e si a C ra n ia l n e rv e d ys fu n ct io n S e m ic ir cu la r ca n a l a n o m a lie s C o n g e n it a l h e a rt d e fe ct R e n a l a n o m a lie s In te lle ct u a l d is a b ili ty G ro w th d e fi ci e n cy G e n it a l h yp o p la si a P it u it a ry p ro b le m s M ic ro p h th a lm ia /c o lo b o m a E xt e rn a l e a r a n o m a lie s H e a ri n g lo ss C le ft lip a n d /o r p a la te O e so p h a g e a l a tr e si a H yp o ca lc a e m ia Im m u n o d e fi ci e n cy figure 3 , we show the overlapping clinical features of CHARGE and 22q11.2 deletion syndrome with known genetic syndromes. All the genes mentioned in this figure or their proteins have been associated with either CHD7 or TBX1. The expression of FGFR1 , OTX2 and TBX1 depends on CHD7 in some tissues; TBX1 and FGF8 are in epistasis in ectodermal development; binding of the protein treacle which is encoded by TCOF1 partly depends on the presence of CHD7, and SOX2 and CHD7 are cofactors that regulate the expression of JAG1, MYCN and GLI3 , amongst others [Randall et al., 2009; Hurd et al., 2010; Zentner et al., 2010a; Engelen et al., 2011; Layman et al., 2011] . Figure 3 shows that the linked molecular pathways are reflected by the shared clinical features of the syndromes.
ing inner ear of a Chd7 null mouse conditional mutant ( Chd7 Gt/Gt ) compared to the wild-type mouse embryo. This effect was not seen in heterozygously mutated mice ( Chd7 Gt/+ ), suggesting that there is a dose-dependent inhibiting effect of Chd7 on Tbx1 in the inner ear which might be essential for inner ear neurogenesis .
As an alternative theory, a shared convergent pathway via fibroblast growth factor 8 (FGF8, OMIM 600483) has been suggested, but has not been proven [Randall et al., 2009] . It was shown that reduced Chd7 dosage in the olfactory placode, pituitary and hypothalamus in mice reduced the expression of the FGF8 receptor Fgfr1 (OMIM 136350) . FGF8 and its receptor FGFR1 are interesting linking factors, since both are also involved in the pathogenesis of other organs frequently affected in CHARGE syndrome, like the combination of hypogonadotropic hypogonadism and anosmia [Pallais et al., 1993; Bergman et al., 2011a Bergman et al., , 2012a . The fact that this combination is seldom seen in patients with 22q11.2 deletion could be explained by the more ubiquitous expression of CHD7 compared to TBX1 .
The tight relationship between 22q11.2 deletion and CHARGE syndrome is not an isolated observation. Both syndromes share common features with other syndromes that may reveal further clues for interaction of their causative genes and underlying embryonic pathways. For instance, SOX2 mutations (OMIM 184429) result in a phenotype characterised by anophthalmia, tracheo-oesophageal abnormalities, pituitary defects, and genital abnormalities. Like CHD7, SOX2 is assumed to play a role in neural stem cells, and Engelen et al. [2011] showed that CHD7 is a SOX2 transcriptional cofactor with their common target genes being JAG1, GLI3 and MYCN (Notch and Shh signalling pathways). Shh signalling regulates the expression of TBX1 in the pharyngeal arch probably through transcription factors of the FOX family [Yamagishi et al., 2003] . TBX1 has also been described as an upstream regulator of the Notch-signalling effector HES1 in the pharyngeal arch and a downstream target of JAG2 in tooth morphogenesis [Mitsiadis et al., 2010; van Bueren et al., 2010] . CHD7 and TBX1 have been described to interact with proteins known from other overlapping syndromes ( fig. 3 ) . Thus, CHD7 and TBX1 may also interact indirectly through different pathways, like the Notch and Shh signalling pathways.
In conclusion, the clinical diagnosis of 2 highly variable syndromes, CHARGE and 22q11.2 deletion syndrome, can prove challenging. The syndromes should therefore be included in a common differential diagnosis, and we strongly recommend performing CHD7 analysis in any patients with a 22q11.2 deletion phenotype but without TBX1 haploinsufficiency and performing a genome-wide array for 22q11.2 deletions in clinical CHARGE patients without a CHD7 mutation. We have shown that there is strong clinical evidence that both molecular pathways are linked, although the precise nature of this link needs further exploration.
